The placebo effect in irritable bowel syndrome trials: a meta‐analysis1

Neurogastroenterology and Motility - Tập 17 Số 3 - Trang 332-340 - 2005
S. M. Patel1, William B. Stason2, Anna Legedza3,4, Sun Myeong Ock4, Ted J. Kaptchuk4, Lisa Conboy4, Katia M. Canenguez3, J. K. Park4, Erik Kelly3, Eric Jacobson4, Catherine E. Kerr4, Anthony Lembo3
1Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
2Division of Gastroenterology, Department of Medicine, Harvard School of Public Health, Harvard, MA, USA
3Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA
4Division of Gastroenterology, Department of Medicine, Osher Institute, Harvard Medical School, Boston, MA, USA

Tóm tắt

Abstract  Background:  Despite the apparent high placebo response rate in randomized placebo‐controlled trials (RCT) of patients with irritable bowel syndrome (IBS), little is known about the variability and predictors of this response.Objectives:  To describe the magnitude of response in placebo arms of IBS clinical trials and to identify which factors predict the variability of the placebo response.Methods:  We performed a meta‐analysis of published, English language, RCT with 20 or more IBS patients who were treated for at least 2 weeks. This analysis is limited to studies that assessed global response (improvement in overall symptoms). The variables considered as potential placebo modifiers were study design, study duration, use of a run‐in phase, Jadad score, entry criteria, number of office visits, number of office visits/study duration, use of diagnostic testing, gender, age and type of medication studied.Findings:  Forty‐five placebo‐controlled RCTs met the inclusion criteria. The placebo response ranged from 16.0 to 71.4% with a population‐weighted average of 40.2%, 95% CI (35.9–44.4). Significant associations with lower placebo response rates were fulfilment of the Rome criteria for study entry (P = 0.049) and an increased number of office visits (P = 0.026).Conclusions:  Placebo effects in IBS clinical trials measuring a global outcome are highly variable. Entry criteria and number of office visits are significant predictors of the placebo response. More stringent entry criteria and an increased number of office visits appear to independently decrease the placebo response.

Từ khóa


Tài liệu tham khảo

10.1136/gut.22.4.323

10.1046/j.1365-2125.1999.00094.x

10.1053/gast.1997.v112.pm9178676

10.1053/j.gastro.2004.01.024

10.1016/S0002-9343(99)00086-8

10.7326/0003-4819-133-2-200007180-00013

10.1016/0016-5085(88)90319-8

10.1111/j.1572-0241.2000.02179.x

10.1159/000171471

10.1111/j.1365-2982.2004.00516.x

10.1016/0197-2456(95)00134-4

10.1007/BF02093778

Agresta A, 1990, Categorical Data Analysis

10.1016/0197-2456(86)90046-2

10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V

10.2307/2533446

10.1136/bmj.315.7109.629

Stata v. StataCorp.Copyright 1984–2003. College Station Texas USA:Stata v. StataCorp.

10.1111/j.1440-1746.1998.tb00723.x

10.1001/jama.287.14.1840

10.1001/jama.1994.03510440069036

10.1016/0304-3959(95)00116-6

10.1016/S0094-0143(02)00038-1

10.1002/14651858.CD001961

10.1111/j.1572-0241.2000.03192.x

10.1159/000069738

10.1136/jme.26.3.188

10.1111/j.0006-341X.2000.00271.x

10.1016/S0197-2456(97)00118-9

10.1056/NEJM200105243442106

10.1136/gut.45.2008.ii69

10.1053/j.gastro.2003.10.011

10.1016/S0002-9270(02)05657-5

Drossman DA, 2000, Rome II. The Functional Gastrointestinal Disorders. Diagnosis, Pathophysiology, and Treatment: a Multinational Consensus

10.1053/gast.2002.37095

10.1016/S0140-6736(76)91402-1

10.1185/03007998009109491

Fielding JF, 1980, Double blind trial of trimebutine in the irritable bowel syndrome, Ir Med J, 73, 377

10.7326/0003-4819-95-1-53

10.1159/000198627

10.1097/00004836-198106000-00009

Guslandi M, 1981, Clinical evaluation of octatropine methyl‐bromide plus diazepam (Valpinax) in the treatment of the irritable bowel syndrome, Clin Trials J, 18, 138

10.1159/000198701

Golechha AC, 1982, Role of ispaghula husk in the management of irritable bowel syndrome (a randomized double‐blind crossover study), J Assoc Physicians India, 30, 353

10.3109/00365528209181108

Arthurs Y, 1983, Double blind trial of ispaghula/poloxamer in the irritable bowel syndrome, Ir Med J, 76, 253

Tripathi BM, 1983, Evaluation of tricyclic compound (Timipramine) vis‐a‐vis placebo in irritable bowel syndrome. Double blind randomized study, J Assoc Physicians India, 31, 201

Chadda VS, 1983, A double blind crossover study of diphenylhydantoin in irritable bowel syndrome, J Assoc Physicians India, 31, 425

Dew MJ, 1984, Peppermint oil for the irritable bowel syndrome: a multicentre trial, Br J Clin Pract, 38, 398

Nash P, 1986, Peppermint oil does not relieve the pain of irritable bowel syndrome, Br J Clin Pract, 40, 292, 10.1111/j.1742-1241.1986.tb07981.x

Ghidini O, 1986, Single drug treatment for irritable colon: rociverine versus trimebutine maleate, Curr Ther Res Clin Exp, 39, 541

10.1136/gut.28.11.1510

10.1136/gut.28.2.221

10.1007/BF01297051

10.1111/j.1365-2036.1988.tb00728.x

Centonze V, 1988, Oral cimetropium bromide, a new antimuscarinic drug, for long‐term treatment of irritable bowel syndrome, Am J Gastroenterol, 83, 1262

10.1007/BF02943704

Yadav SK, 1989, Irritable bowel syndrome: therapeutic evaluation of indigenous drugs, Indian J Med Res, 90, 496

10.1136/gut.31.3.355

10.1097/00004836-199102000-00012

10.1016/0022-3999(92)90026-X

10.1111/j.1365-2036.1994.tb00323.x

10.1111/j.1749-6632.1994.tb44123.x

10.3109/00365529609006766

10.1046/j.1365-2036.1997.133311000.x

10.1046/j.1365-2036.1998.00397.x

10.1080/00365529850166833

10.1016/S0140-6736(00)02033-X

10.1046/j.1365-2036.2001.01094.x

10.1111/j.1572-0241.2001.04128.x

10.1001/archinte.161.14.1733

10.1046/j.1365-2036.2002.01372.x

10.1007/BF02850364

10.1097/00042737-200212000-00008

10.1111/j.1572-0241.2002.07111.x

10.1046/j.1365-2036.2002.01277.x

10.1046/j.1365-2036.2002.01320.x

10.1053/cgh.2003.50019

Thông tin
Thông tin xuất bản

Neurogastroenterology and Motility

Tập 17 Số 3

332-340

Thông tin tác giả